Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine

Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® Junior

“…13,15 Here we present the evaluation of antibody persistence between the second and third doses of the primary vaccination course (6 mo after the first vaccination with either FSME-IMMUN ® Junior or Encepur ® Children) as well as the immunogenicity and safety following the third vaccination (administered approximately one year after the first vaccination) with FSME-IMMUN ® Junior. All subjects received the vaccine intramuscularly into the musculus deltoideus of the upper arm or-depending on the developmental and nutritional status of the child-into the musculus vastus lateralis of the upper leg.…”

Five year follow-up after primary vaccination against tick-borne encephalitis in children

“…Several explanations for this observation have been suggested before [9,18] and include intrinsic differences in the vaccine formulations such as in the antigenic content and/or the excipients added. Ultimately, regardless of their relative differences in immune response, it is well established that both Encepur ® and FSME-IMMUN ® elicit effective immune responses against TBE after a complete primary vaccination series in adults and children [9,11,17,19,20], even if used interchangeably [9,18]. What has not been well established, however, is the duration of antibody persistence following primary immunization with these vaccines.…”

An Inactivated Ross River Virus Vaccine Is Well Tolerated and Immunogenic in an Adult Population in a Randomized Phase 3 Trial

“…More extensive clinical data are available for inactivated, whole-virus vaccines to prevent diseases caused by flaviviruses, which structurally resemble alphaviruses, such as tick-borne encephalitis virus (TBEV), Japanese encephalitis virus, and yellow fever virus (21)(22)(23). The most extensively studied flavivirus vaccine is an alumadjuvanted inactivated whole-virus TBEV vaccine, which has been demonstrated to be safe and immunogenic in a multitude of clinical studies (24)(25)(26)(27)(28)(29)(30) and which has been used in Europe for several decades. In field studies, it has been demonstrated that three immunizations with a 2.4-g dose of the inactivated wholevirus TBEV vaccine provide approximately 99% effectiveness in preventing tick-borne encephalitis (22).…”